Early and effective treatment of cancers could mean the difference between life and death. Therefore, companion diagnostics and biomarker discovery could be considered one of the most important avenues to explore in immuno-oncology.

What is the future of precision medicine for immuno-oncology, and how can we achieve it? In this Insight Article, we sat down with senior representatives from the University of Michigan, the Beth Israel Deaconess Medical Center / Harvard Medical School, and The Institute of Cancer Research, London, to discover more about harnessing the potential of spatial biology and predictive biomarkers to achieve targeted results.

At the 2021 Immuno Week: Online event, we sat down with an advisory board comprised of key figures from some of the top biotech companies and research institutions to discuss the acute need for improved combination therapies and predictive biomarkers in immuno-oncology.

Patient-specific medicine in Immunotherapy and Immuno-oncology is fast becoming a globally recognised form of cancer treatment. But how easy is it to apply AI and ML to tailor a treatment for each individual patient? Director of Genomic Immuno-Oncology at Evaxion Biotech, Jens Kringelum, investigates how best to integrate data generation and ML to decode the immune system.

Peter H Schafer, Executive Director, Translational Development, Celgene

Zhongwu Lai, Principal Scientist, Cancer Informatics, AstraZeneca

Andrea Murray, Chief Operational Scientist, Oncimmune Ltd.

Statistics, Delegate & Solution Provider Testimonials,

Geert Mudde, Chief Scientific Officer, OncoQR ML GmbH